| Element List | Current Year | Previous Year | %Change | ||
|---|---|---|---|---|---|
| Sales/Revenue | 1,600,362 | 1,293,685 | 23.7 | ||
| Gross Profit (Loss) | 588,902 | 451,208 | 30.52 | ||
| Operational Profit (Loss) | 354,537 | 293,420 | 20.83 | ||
| Net Profit (Loss) Attributable to Shareholders of the Issuer | 318,470 | 294,699 | 8.07 | ||
| Total Comprehensive Income Attributable to Shareholders of the Issuer | 309,549 | 296,418 | 4.43 | ||
| Total Shareholders Equity (after Deducting Minority Equity) | 1,849,213 | 1,626,041 | 13.72 | ||
| Profit (Loss) per Share | 7.13 | 6.58 | |||
| All figures are in (Thousands) Saudi Arabia, Riyals | |||||
| Element List | Amount | Percentage of the capital (%) | |
|---|---|---|---|
| Profit (Losses) Resulting From The Change In Investment Propertie’s Fair Value | - | - | |
| All figures are in (Thousands) Saudi Arabia, Riyals | |||
| Element List | Explanation |
|---|---|
| The reason of the increase (decrease) in the sales/ revenues during the current year compared to the last year | Net revenue of SAR 1,600.4 million (FY 2024: SAR 1,293.7 million) for the current year, reflecting a 24% growth compared to the previous year due to the following: • A 33% increase in total patient volumes to 985,088 patients. • Higher referrals from key clients, including GOSI, MoH, government-related entities, and insurance companies, resulting in higher inpatient and outpatient revenue. • Revenue growth across all facilities, supported by the full-year contribution of Al Salam Hospital and continued expansion of the ReLib platform. |
| The reason of the increase (decrease) in the net profit during the current year compared to the last year is | Net profit of SAR 318.5 million (FY 2024: SAR 294.7 million) for the current year, representing an 8% increase compared to the previous year, due to the following: • Strong revenue growth of 24% year-on-year. • Lower cost of sales as a percentage of revenue, at 63% compared to 65% in FY 2024, reflecting improved operating leverage and cost efficiencies. • Improved gross profitability, with gross profit increasing 31% year-on-year and gross margin expanding to 37% (FY 2024: 35%). • Lower expected credit loss (ECL) provisions of SAR 17.8 million (FY 2024: SAR 32.7 million), reflecting improved collection frameworks. • Higher operating profits are supported by gross profit growth and lower ECL provisions. • EBITDA growth to SAR 465.2 million (FY 2024: SAR 377.4 million), with EBITDA margin at 29%, largely unchanged from last year. The net profit growth of 8% in the current year reflects a high base effect in FY 2024, when net profit had benefited from one-off reversals of legal and zakat provisions amounting to SR 72 million. Excluding these items, net profit increased by 43% year on year basis. |
| Statement of the type of external auditor's report | Unmodified opinion |
| Comment mentioned in the external auditor’s report, mentioned in any of the following paragraphs (other matter, conservation, notice, disclaimer of opinion, or adverse opinion) | None |
| Reclassification of Comparison Items | Certain prior year figures have been updated to reflect additional depreciation charge as a result of the finalisation of purchase price allocation to the identifiable assets and liabilities related to the acquisition of a subsidiary. Refer to note 14 for details. |
| Additional Information | - |
| Attached Documents | Attached Documents |
